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OBJECTIVES: Bankruptcy may be a particular concern for cancer patients. Costs
from treatment and supportive care, along with non-medical costs such as lost
income, can be financially devastating. We estimated the incidence of bankruptcy
following cancer diagnosis using linked cases from the Washington SEER registry
withWestern District ofWashington bankruptcy court records.METHODS: Cancer
cases (age20) were identified for 1995-2009. Our analyseswere limited to patients
reporting their first primary cancer, excluding cancers in situ or diagnosed at time
of death. To determine the proportion of cancer cases reporting personal bank-
ruptcy (Chapter 7 or 13) following cancer diagnosis, we generated cumulative inci-
dence (CI) of bankruptcy, to allow for the competing risk of death.We calculated CI
using Gray’s method to compare bankruptcies among different cancers. RESULTS:
There were N231,799 cancer cases; after a mean follow-up of 4.3(sd4.1) years,
N4805 (2.1%) had filed for bankruptcy after cancer diagnosis. Average age at di-
agnosis of filers was 52.8(sd13.6) years and 55% were female compared to
63.9(sd14.6) years and 49% female for all cancer cases (p0.0001 for both compar-
isons). Mean andmedian time to bankruptcy was 3.3 and 2.5 years, respectively. At
1, 2 and 3 years following diagnosis, the proportion of bankruptcies filed was 23%,
41%, and 56%, respectively. By 3 years, the incidence of bankruptcy was 1.3%.
Thyroid cancer had the highest CI at 3 years (2.7%), followed by uterine (1.7%),
melanoma (1.6%), breast (1.6%), leukemia/lymphoma (1.4%), colorectal (1.2%), lung
(1%) and prostate (0.9%); the CI for all other cancers was 1.3%. The overall CI of
bankruptcy was 3.3%. CONCLUSIONS: Two in 100 patients file for bankruptcy fol-
lowing a cancer diagnosis. Thyroid and uterine cancer have the highest incidence
of bankruptcy. Factors associated with bankruptcy following cancer are yet to be
determined.
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OBJECTIVES: Patients treated for neuroendocrine tumors and acromegaly have to
be periodically injected with a long-acting somatostatin analog (SSA). This study
aimed at evaluating the economic implications of using a new pre-filled device for
Somatuline Autogel/Depot versus Sandostatin LAR. The study was performed in
three European countries and the US. METHODS: A quantitative study was per-
formed in France, Germany, the UK and the US, including 77 nurses. The majority
of nurses were from hospital wards, specialized in endocrinology and oncology.
The number of SSA patients per nurse was at least 3 per year. Time spent for each
injection and number of clogging episodes was recorded per nurse and per type of
injection (Somatuline new device or LAR). Cost of successful injection was calcu-
lated per patient / per nurse using retail costs for the 4 countries. RESULTS: With
LAR, 2 clogging incidents were reported. This led to an average of 79 injections for
LAR vs. 77 for Somatuline new device. The calculated cost per successful injection
for the 4 countries pooled together was in Euro: 1’603 and 1’628 respectively for
Somatuline new device and LAR. The incremental cost between the 2 treatments
was EUR 25 per injection. Assuming an 85% compliance, this translated up to EUR
255 per patient per year. When considering only the 3 European countries, the
annual difference was EUR 724. CONCLUSIONS: The usage of a new pre-filled So-
matuline device for the injection of SSA could lead to substantial savings for hos-
pitals and health-care payers. Due to the differences in retail prices across coun-
tries, these savings could potentially be even more significant in Europe.
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OBJECTIVES: Heterogeneity of treatment effects and variation in expenditures
across subgroups impact the cost-effectiveness of health care interventions. This
study investigates the variation in costs, effects, and incremental cost-effective-
ness ratios (ICERs) associatedwith chemotherapy receipt in elderlymetastatic (M1)
prostate cancer (PC) patients across race/ethnicity subgroups (Non-Hispanic
Whites, Non-Hispanic Blacks, Others). METHODS: We examined patients aged 66
or older identified using linked Surveillance, Epidemiology and End Results (SEER)-
Medicare data, who were diagnosed with M1 PC between 2000 and 2005. Cost data
based on Medicare reimbursements were available for 36 months after diagnosis.
Mean costs and effects (life-years gained, LYG) were adjusted for censoring using
inverse probability weighting. The baseline scenario examined PC-specificmedical
costs up to 24 months and required patients to be alive for at least 3 months after
diagnosis. Sensitivity analysis considered sampling uncertainty, selection into
treatment, and adjustments to initial model assumptions. RESULTS:We identified
3,888 M1 PC patients, of which 24% (N930) received chemotherapy (mostly do-
cetaxel andmitoxantrone). Twenty percent of observationswere censored. The full
sample ICER was $99,146 per LYG (95% CI: $75,041-$130,194). Compared to Whites
($107,095; CI: $78,391-$148,272), ICER point estimates were lower for Blacks
($59,887; CI: $22,860-$121,509) and higher for Others ($123,909; CI: $37,782-
$366,376). We also observed substantial variation across racial subgroups in the
probability of chemotherapy being cost-effective given various willingness-to-pay
thresholds per LYG. Results were similar in sensitivity analysis. CONCLUSIONS:
Chemotherapy use in elderly M1 PC patients is associated with an ICER of $99,146
per LYG in our sample. Subgroup analysis revealed racial heterogeneity in ICER
point estimates and considerable statistical uncertainty. In order to generate a
reliable evidence base for personalized medicine, efforts to increase the represen-
tation ofminorities in clinical trials, registries, and other health care datasets need
to continue.
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OBJECTIVES: Renal cell carcinoma (RCC) is the most common primary renal ma-
lignant neoplasm in adults. It accounts for approximately 90% of renal tumors and
2% of all adult malignancies. The purpose of this study was to estimate the cost-
effectiveness of temsirolimus versus interferon- for patients treated as first line
with metastatic renal-cell carcinoma and poor prognosis from an institutional
perspective. METHODS: A three-state Markov model was performed to estimate
health and economic consequences during a time horizon of 12 months (six–week
cycles). Effectiveness measures were: overall survival, progression-free survival
(months), and quality adjusted life years gained (QALYs). Drug safety was also
assessed (grade 3-4 adverse events-AE). Transition probabilities were obtained
from a meta-analysis collecting international published literature data. Doses of
comparators were: temsirolimus (25mg/week) and interferon- (41,380,000 IU/
week). Resource use was obtained from Social Security Mexican Institute hospital
records (n154). Costs were extracted from institutional sources and include: hos-
pitalization, drugs, medical procedures, laboratory tests and adverse events man-
agement. Probabilistic sensitivity analyses were performed and acceptability
curves were constructed. RESULTS: Temsilorimus overall survival resulted in 10.9
months (CI 95% 10.63 – 11.17) and interferon- achieved 7.3 months (7.09 – 7.51)
(p0.05). For progression-free survival, temsirolimus estimation was 5.5 months
(5.36 – 5.64) and interferon- exhibited 3.1 months (3.01 – 3.19) (p0.05). Lastly,
temsirolimus raised QALYs in 0.74 (0.72 – 0.76), (p0.05), and diminished grade 3-4
hematologic AE in9.59% (9.35% -9.83%), (p0.05). Incremental cost-effective-
ness ratio (ICER) for overall survival and progression-free survival for temsirolimus
against interferon- were US$4,839 [US$4,718-US$4,961] and US$7,259 [US$7,077-
US$7,441], respectively. The ICER using QALYs resulted in US$23,458 [US$22,869-
US$24,046]. Probabilistic sensitivity analyses showed that results were robust.
CONCLUSIONS: Regarding overall survival, progression–free survival and QALYs
temsirolimus represents a cost-effective therapy in Mexican patients who suffer
metastatic renal-cell carcinoma and poor prognosis.
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OBJECTIVES: National guidelines recommend a 21-gene Recurrence Score (RS) to
aid in adjuvant treatment decision in estrogen-receptor-positive, node-negative
early stage breast cancer (ER, LN- ESBC) patients. To assess the economic impli-
cation of the assay in community practices from the perspective of an US payer.
METHODS: Analysis of 952 women with ESBC enrolled with Humana, Inc. (Louis-
ville, KY) tested with the 21-gene RS between June, 2006 and June, 2010. The pro-
portion of women classified by the assay by RS risk categories, utilization and costs
of chemotherapy regimens, and supportive care, and costs of adverse events were
obtained fromHumana.We adapted a validatedMarkovmodel to compute the cost
implications of RS for a representative patient. The probability of risk of recurrence,
chemotherapy benefits and decision impact of RS were derived from published
studies. RESULTS: 255 patients within the tested population received adjuvant
chemotherapy. Adjuvant chemotherapywas administered to 10% of women at low
risk, 36% of women at intermediate risk, and 72% of women at high risk of recur-
rence. Based on a meta-analysis in the reduction of chemotherapy after RS, the
model estimated an average per patient test saving of $1,115. The immediate direct
savings for chemotherapy drug, supportive care, and management of adverse
events were $1,897, $2,593, $475, respectively. Prevention of recurrence through
appropriate treatment of high-risk patients resulted in additional saving of $126.
CONCLUSIONS: The adoption of the 21-gene RS lead to targeted management of
women with ER, LN- ESBC, and consequently save direct medical costs.
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IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR
ER HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-
EFFECTIVE?
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OBJECTIVES: Approximately 60% of breast cancer cases are a type sensitive to
hormones. Tamoxifen is the most widely used treatment of hormone-dependent
breast cancer. The pharmacological activity of tamoxifen is dependent on its con-
version by the hepatic drug–metabolizing enzyme CYP2D6. Patients with reduced
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CYP2D6 activity derive inferior therapeutic benefit from tamoxifen, andmay alter-
natively be treated with newer aromatase inhibitors (AIs). However, the high costs
of AIs provide incentive for identifying patients who will benefit from tamoxifen
prior to treatment. We estimated the cost-effectiveness of genetic testing in com-
bination with hormone therapy for early breast cancer in Canada. METHODS:We
performed a cost-effectiveness analysis using a Markov model from a societal per-
spective and a lifetime horizon. The base case assumed 40-year-old ER hormone
sensitive women with early breast cancer. We evaluated: genetic testing with sub-
sequent treatment based on genetic status (tamoxifen for CYP2D6 extensive me-
tabolizers and AIs for decreased metabolizers) vs. no testing (tamoxifen for all
patients). Probabilistic sensitivity analysis was used to incorporate parameter un-
certainties. Expected value of perfect informationwas performed to identify future
research directions. Outcomes were quality-adjusted life years (QALYs) and costs.
RESULTS: The genetic testing and treatment combination strategy resulted in a
2.87 QALY gain when compared to no testing. The incremental cost was CAD
$25,661 compared to standard care, and the incremental cost-effectiveness ratio
(ICER) for the base case was $8,927 per QALY. The ICER was sensitive to disease
progression among intermediate metabolizers, and costs of terminal care and aro-
matase inhibitors. CONCLUSIONS: CYP2D6 Genetic testing in combination with
hormone treatment for early breast cancer patientsmay be economically attractive
in the current setting. Future research is required to determine efficacy of extended
tamoxifen (more than 5 years) treatment, the rate of progression to a more ad-
vanced cancer health state and adverse events by CYP2D6 polymorphism.
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CANCER ERBB2 AFTER PROGRESSION TO THE FIRST SCHEME OF
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OBJECTIVES: To develop a cost-effectiveness analysis of LC versus TC in the treat-
ment of metastatic breast cancer ErBb2 after progression to one regime of
trastuzumab. METHODS: A Markov model was designed with one week length
cycles, two years time horizon and two stages: Free of Progression and Progression.
The analysis was conducted from the perspective of the Mexican public Health
System for patients who had progressed to the first scheme of trastuzumab
(around 900 patients). Efficacy data for this specific population was based on and
ad-hoc sub analysis reported by Cameron 2010 for LC: 0.50, p0.001 and per proto-
col population reported by Minckwitz 2009 for TC: 0.69, p0.034. Baseline analysis
used time to progression for monotherapy reported by Minckwitz and an univari-
ate sensitivity analysis was run with monotherapy results by Cameron. Govern-
ment prices were used for capecitabine (2000 mg/m2/day), lapatinib (1250 mg/day)
and trastuzumab (2mg/kg/week). One chemotherapy session costwas added every
three weeks in the trastuzumab arm. Results are reported in US dollars. RESULTS:
Cost-effectiveness ratio for LC and TC was $650.82 and $756.86 respectively. LC
group had an average incremental effectiveness of 7.47 weeks free of progression
and an incremental cost of $371.74 (ICER$49.74). The acceptability curve showed
that with a willingness to pay above $480.16 per free of progression week the 100%
of cases would be cost-effective. In the univariate sensitivity analysis the LC group
gained 8.04 weeks free of progression with an incremental cost of $225.60 com-
pared to TC (ICER$28.04). CONCLUSIONS: According to this analysis the LC group
gained 7.47weeks free of progressionwith an extra cost of $371.74 ($49.74 perweek)
compared to TC. The LC grouphad a lowermonthly cost of treatment ($650.82) than
TC ($756.86). LC is cost-effective with a willingness to pay above $480.16 per extra
progression free week.
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OBJECTIVES: To assess the cost-effectiveness of a single-dose Pegfilgrastim 6mg
subcutaneously at day 5 versus Filgrastim 5g/kg/day subcutaneously from D5 to
resolution of neutropenia (absolute neutrophil count ANC0.5G/L) after stem cell
reinfusion in adult patients with lymphoma or myeloma, which is one of the first
studies on observational data.METHODS: Cost-effectiveness was assessed within
an open, multicentre randomized phase-II trial. The time horizon was 100/10
days from stem cell transplantation. Cost computation, using a microcosting ap-
proach focused on inpatient and home care, and cost distributions between the
two treatment armswere compared using theMann-Whitney test. Multiple regres-
sion analyses were performed in order to identify cost drivers. Incremental cost-
effectiveness ratios (ICERs) were based on the number of days with 1) febrile neu-
tropenia (ANC0,5G/L and temperature 38°C), 2) neutropenia (ANC1.0G/L), 3)
thrombopenia (platelets20.0G/L), and 4) temperature (38°C). Uncertainty
around ICERs was evaluated using Filler’s method and Monte Carlo simulations.
RESULTS: 151 patients were enrolled (October 2008/September 2009). One was not
evaluable due to missing data. Average total costs reached 25,024€ (SD 9,945€) for
Pegfilgrastim (n74) versus 28,700€ (SD 25,165€) for Filgrastim (n76), with 22,061€ (SD
8,101€) versus 25,165€ (SD 16,572€) for hospitalisation; 1,217€ (SD 2,039€) versus 1,444€
(SD 3,367€) for anti-infectious treatment; 1,106€ (SD 1,132€) versus 1,329€ (SD 2,598) for
transfusions; and 639€ (SD 89€) versus 762€ (SD 230€,) for growth factors, respectively.
The cost of growth factors significantly decreased with Pegfilgrastim, in women, in
patients with previous induction. Pegfilgrastim dominated Filgrastim for number of
days with febrile neutropenia, neutropenia, thrombopenia, and temperature. On the
two-fold basis of their cost and their medical effectiveness, Pegfilgrastim dominated
Filgrastim based on the 82% confidence region. CONCLUSIONS: From these results
there seems to be no restriction to the prescription of Pegfilgrastim in lymphoma and
myelomapatients after high-dose chemotherapy and autologous stemcell transplan-
tation.
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OBJECTIVES: Evaluate the cost-effectiveness of addition one-year adjuvant trastu-
zumab therapy to standard adjuvant chemotherapy in treatment of HER2 breast
cancer (BC) early stage from a societal perspective in a Russian setting.METHODS:
We used a Markov state transition model to simulate adjuvant trastuzumab treat-
ment in a hypothetical cohort of early breast cancer patients for lifetime horizon.
Patients were treated with a combination of chemotherapy and 1-year trastu-
zumab therapy (HT  T) or only with chemotherapy (HT). The transition probabil-
ities between states in the Markov model, the effectiveness and usefulness of
treatment were obtained from clinical studies HERA, 2005 and other published
data. Costs for each state Markovmodel based on the standard treatment of breast
cancer in Russia. Data about cost of medical services and drugs are received from
the price-list of out-patient medical aid in clinic MMA of I.M.Sechenov 10.01.2010,
site minzdravsoc.ru//medicine and other accessible electronic resources. Costs,
effectivenesses, utilities were discounted at 3%. Sensitivity analysis for key param-
eters in the model was conducted. RESULTS: On the basis of Markov model with
lifetime horizon, CTT has an incremental cost-effectivesness ratio (ICER) of
860.704 roubles per LYG and incremental cost-utility ratio (ICUR) of 986.015 roubles
per QALY. According to our threshold analysis, additional expenses on additional
QALY are in a comprehensible range (825.0001.650.000 roubles), that has allowed
to make the conclusion about an acceptability of one-year use trastuzumab in
treatment of patients HER2  breast cancer at early stages. Sensitivity analysis
showed thatmajor factors influencing cost-effectiveness and cost-utility ratios are
survival gain, price of trastuzumab, discount rates. CONCLUSIONS: The combina-
tion 1-year adjuvant trastuzumabwith standard chemotherapy ismore cost-effec-
tive and cost-useful in comparison with standard chemotherapy for patients HER2
 breast cancer at early stages.
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OBJECTIVES: The cost-effectiveness of different Human Papillomavirus (HPV) vac-
cination programmes was already confirmed throughout a large body ofmodelling
studies. An excess of uncertainty associated with the main parameters of com-
monly utilized models can be observed. The aim of this study was to assess the
cost-effectiveness of a quadrivalent-based multi-cohort HPV vaccination strategy
using a statistical Bayesian approach. METHODS: A full Bayesian Markov model
was used, where all unknown quantities were associated with suitable probability
distributions reflecting the state of science currently available. These distributions
were updated by the observation of any Italian available data, and uncertainty was
propagated through the entire model with a Markov Chain Monte Carlo procedure.
The model was calibrated using age-specific incidence of invasive cervical cancer
data. RESULTS: Base case (2 cohorts of girls aged 12 and 15 years) and other multi-
cohort vaccination strategies under evaluation (3 and 4 cohorts) were cost-effective
with a discounted cost per QALY gained corresponding to €12,013 (95% range €2,364
- €22,481), €13,232 (95% range €4,432 - €22,939), and €15,890 (95% range €7,179 -
€25,139) for vaccination programmes based on 2, 3 and 4 cohorts, respectively. The
overall expected effect of vaccination seems to be linked with the number of co-
horts targeted. With a multi-cohort vaccination the combined reduction of HPV-
related events occurred progressively early (range 3 – 6.5 years) compared with the
vaccination of a single cohort. The analysis of the expected value of information
showed that the uncertainty was always kept at a low level among different multi-
cohort strategies. The cost associated with the achievement of the expected value
of information ranged between €9 and €13 per patient. CONCLUSIONS: The qua-
drivalent-based multi-cohort HPV vaccination programme can provide excellent
value for money spent and the Bayesian expected value-of-information analysis
provides the most appropriate and feasible representation of this program’s true
value.
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